The use of amorphous form of drug substances to improve solubility, accelerate dissolution, and promote therapeutic activity has been very important for the development for water insoluble solids as pharmaceutical dosage forms.
1)However, not only chemical degradation 2) but also physical change such as crystallization 3,4) and aggregation 5,6) of amorphous solids even below their glass transition temperature (Tg) were reported, and these instabilities of most amorphous solids preclude their more widespread use in pharmaceutical dosage forms. Such advantages and disadvantages are offered due to excess properties of amorphous systems in terms of enthalpy and free energy. These high energy systems are unstable and tend to spontaneously revert back to the thermodynamically stable state. Thus, amorphous solids may crystallize, or even if crystallization does not occur on pharmaceutical shelf life, amorphous solids will 'relax' toward the equilibrium supercooled liquid state as shown in Fig. 1. As a glass moves towards the equilibrium state, energy decreases, free volume decreases, and structural order increases, i.e., configurational entropy decreases. Thus, this process is called structural relaxation. As the intact amorphous state indicated in Fig. 1 is of higher enthalpy than the equilibrium state, heat is given off during the relaxation process, and this process is known as enthalpy relaxation. This process has strong temperature dependence, and the relaxation rate is maximal close to the Tg while negligible relaxation occurs at temperatures far below it. This means that relaxation of the amorphous materials would occur during pharmaceutical unit operations involving thermal or mechanical stresses. For glassy polymers, time dependent changes in physical and mechanical properties are often attributed to relaxation.7) This includes increase in density, yield stress, and modulus and decrease in creep and stress relaxation rate.8) Aging procedure is also known to increase the brittleness and lower the impact strength of glasses.
9)Thus, there is a large possibility that aging should affect the physical properties of amorphous solids, and those studies in pharmaceutical systems have focused on the measurement of relaxation times in relation to the stability prediction based on their molecular mobility. 10,11) Despite that amorphous drug substances can take various enthalpy states, there are few studies 12) to investigate its effect on their properties. FK888 (NK1 antagonist) is a candidate drug for migraine, and is developed as dry powder inhalers (DPIs) to avoid the first-pass effect and minimize unwanted side effects. The solid state of FK888 drug substance is adopted to be amorphous considering its low solubility in aqueous solution, and it is confirmed that the amorphous state is obtained constantly in industrial scale size. In the dosage form of DPIs, because the respirable fraction of the emitted dose is largely dependent on the geometric size of bulk drug particles, not * To whom correspondence should be addre...